Navigation Links
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Dose Escalation Trial with Tovaxin for Multiple Sclerosis

ion of CD8+ cytotoxic T-cells and CD4+CD25+FoxP3 Tregs specific for T-cell vaccine. The induction of anti-idiotypic cytotoxic CD8+ effector T-cells and anti-ergotypic CD4+CD25+FoxP3 positive Tregs is believed to provide a therapeutically effective dual mechanism of protection to patients treated with Tovaxin(TM). The observed regulatory immune responses have been shown to collectively correlate with clinical improvement in treated patients.

About Opexa Therapeutics

Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin(TM), a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for diabetes mellitus. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about Opexa Therapeutics' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Opexa Therapeutics' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
3. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:8/28/2014)... , Aug. 28, 2014 Nonin Medical, Inc., ... in noninvasive medical monitoring, today announced that the Food ... 3231 OEM/eHealth finger pulse oximeter for use in ... oximeter plugs into a telemedicine hub or kiosk through ... rate in pediatric to adult patients. The Model 3231 ...
(Date:8/28/2014)... R.I. , Aug. 28, 2014  In recognition ... developing health complications from the flu, pneumonia, shingles ... ® have declared September to be Senior ... they age, it is important that adults ages ... on their vaccinations. CVS pharmacists and MinuteClinic nurse ...
(Date:8/28/2014)... Pa. , Aug. 28, 2014  Robotic ... patients, and media, both for the promise of ... safety. The quick deployment of surgical robots and ... are prompting facilities to evaluate their robotic surgery ... entire surgical team.    ECRI Institute ...
Breaking Medicine Technology:Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5
... 25, 2007 - Reata,Pharmaceuticals, Inc. today announced ... company's Synthetic Triterpenoid programs in,the May 2007 ... The article, "Triterpenoids and rexinoids as multifunctional,agents ... by researchers,and Reata scientific collaborators from the ...
... - Introgen,Therapeutics, Inc. (NASDAQ:INGN) today announced the publication ... survival,pathway impacts the anticancer activity of INGN 241. ... tumor killing effects of,INGN 241 in cell culture ... Introgen and The University of Texas M. D. ...
Cached Medicine Technology:Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 2Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 3Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 4Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 2Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 3
(Date:8/28/2014)... To kick off the fall season ... One Spas retailers across the country are offering 0% ... The Hot Tub Tailgate Event is from August 29th-September ... more information and to apply early! , As the ... wide variety of outdoor hot tubs with exclusive features ...
(Date:8/28/2014)... 28, 2014) A fortuitous collaboration at Rice ... a recently discovered natural antibiotic. , The laboratory ... someday help bolster the fight against bacteria that ... around the world. , As part of ... structural biologist Yousif Shamoo and their colleagues created ...
(Date:8/28/2014)... researchers place glue directly on the nerve stumps, but ... and allows glue to easily invade the nerve ends. ... to insert the nerve ends into the conduit because ... Xiangdang Liang and co-workers from the General Hospital of ... technique and defined the best parameters for its use ...
(Date:8/28/2014)... be treated with nasal septum cells. Researchers at the ... cells taken from the nasal septum are able to ... can thus repair articular cartilage defects. The nasal cartilage ... environment is associated with the expression of so-called HOX ... has published the research results together with the report ...
(Date:8/28/2014)... OTTAWA, August 28, 2014 One in every 200 ... with the number of people living with the disease ... according to a study by researchers at the Institute ... Eastern Ontario (CHEO), and the Ottawa Hospital Research Institute. ... prevalence in the world. , The study, published this ...
Breaking Medicine News(10 mins):Health News:Synthesis produces new antibiotic 2Health News:Synthesis produces new antibiotic 3Health News:Synthesis produces new antibiotic 4Health News:From nose to knee: Engineered cartilage regenerates joints 2Health News:Ontario has one of the highest rates of IBD in the world 2
... caries can destroy most of a child,s teeth by ... Indians and Alaskan natives. Although the link between ... has been known for almost a century, progress in ... the disease has remained elusive. The ...
... The American College of Physicians (ACP) today told the ... including enacting a permanent end to scheduled Medicare sustainable ... for Congress to act was demonstrated by today,s release ... across-the-board cut in Medicare payments to doctors on January ...
... , THURSDAY, Nov. 3 (HealthDay News) -- Allergy ... costs and can now provide relief to allergy sufferers ... And while allergy shots are currently given under the ... investigated, delegates heard at this week,s annual scientific meeting ...
... the first time, researchers have combined gene therapy ... severe, crippling bleeding disorder hemophilia A in large ... new therapies for human patients. Researchers at ... Medicine, collaborating with other institutions, report in ...
... HealthDay Reporter , WEDNESDAY, Nov. 2 (HealthDay News) -- ... subset of hard-to-treat hemophilia patients also seems to be effective ... this study, published in the Nov. 3 edition of the ... one and didn,t last long, the results do raise the ...
... Men with locally advanced or high-risk prostate cancer who ... are less likely to die from their disease, shows ... Margaret Hospital (PMH) Cancer Program, University Health Network. ... Lancet (doi: 10.1016/S0140-6736(11)61095-7). Principal investigator Padraig Warde, ...
Cached Medicine News:Health News:NYUCD awarded $2.2 million NIH grant to decode genome of caries-causing bacteria 2Health News:NYUCD awarded $2.2 million NIH grant to decode genome of caries-causing bacteria 3Health News:Congress must 'go big' on physician payment reform 2Health News:Congress must 'go big' on physician payment reform 3Health News:Improved Allergy Shots Might Be on Horizon 2Health News:Gene therapy shows promise as hemophilia treatment in animal studies 2Health News:Using Drug for Prevention Might Help in Hard-to-Treat Hemophilia 2Health News:Using Drug for Prevention Might Help in Hard-to-Treat Hemophilia 3Health News:Radiation plus hormone therapy greatly improves survival 2
... Unique product designed for LASIK surgery ... to irrigate the corneal interface and/or stromal ... the flap and helps elevate the flap ... 7/8in (.40 x 22mm) Formed 9mm from ...
... designed for LASIK surgery and other types ... corneal interface and/or stromal bed. Flattened tip ... helps elevate the flap edge. Multiple ports ... x 22mm) Formed 9mm from end. Two ...
... designed for LASIK surgery and other ... irrigate the corneal interface and/or stromal ... under the flap and helps elevate ... multi-directional irrigation. 25G x 7/8in (.50 ...
... Cannula tip is specially ... insertion through wound and manipulation ... x 3.5mm, flexible tubing 25cm, ... 2mm. Unique annular rings ...
Medicine Products: